Lodestone Wealth Management LLC Invests $8.37 Million in BioNTech SE

Lodestone Wealth Management LLC recently made a substantial investment in BioNTech SE (NASDAQ:BNTX) during the third quarter, as revealed in its latest 13F filing with the Securities and Exchange Commission (SEC). The firm acquired a total of 70,500 shares of BioNTech's stock, amounting to approximately $8,373,000. This investment represents 4.1% of Lodestone Wealth Management’s total holdings, making BioNTech its largest asset.

Engagement of Other Investors

Other notable investors have also adjusted their stakes in BioNTech. Covestor Ltd increased its holdings by 47.2% in the first quarter, resulting in ownership of 415 shares worth $38,000 after acquiring an additional 133 shares. In the third quarter, Blue Trust Inc. enhanced its position by 491.1%, now holding 467 shares valued at $55,000 after buying an extra 388 shares. EverSource Wealth Advisors LLC raised its stake by 106.3% earlier this year, with total ownership of 489 shares worth $43,000 after purchasing an additional 252 shares.

Additionally, GAMMA Investing LLC grew its position by 86.9% in the second quarter, now owning 512 shares that amount to $41,000 after adding 238 shares. Crewe Advisors LLC has also recently bought a new position in BioNTech valued at approximately $75,000. Overall, institutional investors currently hold about 15.52% of BioNTech's stock.

BioNTech's Stock Performance

As of recent trading, BioNTech shares opened at $111.48. The company boasts a market capitalization of $26.51 billion, with a price-to-earnings ratio of -49.33 and a beta of 0.26. The stock has a fifty-day moving average of $109.72 and a 200-day moving average of $95.77. In terms of liquidity, BioNTech has a quick ratio of 7.40 and a current ratio of 7.54, reflecting its solid financial situation with a debt-to-equity ratio of only 0.01. The stock has fluctuated between a 52-week low of $76.53 and a high of $131.49.

Recent Financial Results

On August 5th, BioNTech announced its quarterly earnings, reporting a loss of $3.36 per share, which fell short of analysts' expectations of a loss of $2.02 by $1.34. The company recorded a negative net margin of 18.69% and a negative return on equity of 2.54%. BioNTech's revenue for the quarter was reported at $128.70 million, below the consensus estimate of $134.98 million, reflecting a decline of 23.3% compared to the same quarter last year. Projections suggest that the firm may post an EPS of -2.93 for the current fiscal year.

Analyst Ratings and Outlook

Various analysts have recently provided updates on BioNTech's stock. UBS Group raised its price target from $97.00 to $131.00 while maintaining a "neutral" rating. JPMorgan Chase shifted its rating from "underweight" to "neutral" and increased its target price from $91.00 to $125.00. TD Cowen also raised its price target from $85.00 to $132.00, and Jefferies Financial Group upgraded the stock from a "hold" to a "buy" rating, with a new target of $150.00. Furthermore, HSBC upped its target from $97.00 to $136.00 and categorized the stock as "buy." Among the analysts, five rate BioNTech as a hold, eight as a buy, and one as a strong buy, leading to an overall average rating of "Moderate Buy" with a price target of $135.54.

About BioNTech SE

BioNTech SE focuses on the development and commercialization of immunotherapies aimed at treating cancer and infectious diseases. The company is exploring several product candidates in their FixVac line, including BNT111 for advanced melanoma (Phase II), BNT112 for prostate cancer (Phase I/IIa), and BNT113 for HPV 16+ head and neck cancers (Phase II). BNT114 targets triple-negative breast cancer, BNT115 is in Phase I for ovarian cancer, and BNT116 is in Phase I trials for non-small cell lung cancer.

Investment, BioNTech, Funds